JDM  Vol.4 No.1 , February 2014
Treatment of peripheral diabetic neuropathy in Zucker diabetic fatty (ZDF) rats with cariporide
Abstract: To determine the effect of Na+/H+-exchanger-1 on diabetic neuropathy in Type 2 diabetes Zucker diabetic fatty (ZDF) rats and lean controls were treated with cariporide (10 or 20 mg/kg/d), a Na+/H+-exchanger-1 inhibitor, for 4 weeks at 15 weeks of age. Neuropathy endpoints included motor (MNCV) and sensory (SNCV) nerve conduction velocities, thermal nociception, tactile allodynia and intraepidermal nerve fiber density. Advanced glycation endproduct and markers of oxidative stress including nitrated protein levels in sciatic nerve and dorsal root ganglion were also evaluated. Expression of Na+/H+-exchanger-1 in dorsal root ganglion neurons was increased in ZDF rats. At 15 weeks of age ZDF rats displayed hyperglycemia, MNCV and SNCV deficits, thermal hypoalgesia and tactile allodynia. At 20 but not 10 mg/kg/d, cariporide significantly improved MNCV and SNCV deficits, thermal hypoalgesia and tactile allodynia. Cariporide treatment was also associated with reduction of diabetes-induced accumulation of advanced glycation end-product (AGE), oxidative stress and nitrated proteins in sciatic nerve and dorsal root ganglion neurons. In conclusion, these findings support an important role for Na+/H+-exchanger-1 in peripheral diabetic neuropathy, and provide rationale for development of Na+/H+-exchanger-1 inhibitors for treatment of diabetic neural complications.
Cite this paper: Lupachyk, S. , Shevalye, H. , Watcho, P. , Obrosov, A. , Obrosova, I. and Yorek, M. (2014) Treatment of peripheral diabetic neuropathy in Zucker diabetic fatty (ZDF) rats with cariporide. Journal of Diabetes Mellitus, 4, 59-66. doi: 10.4236/jdm.2014.41011.

[1]   Callaghan, B.C., Little, A.A. and Feldman, E.L. and Hughes, R.A. (2012) Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane database of systematic reviews, 6, Article ID: CD007543.

[2]   Vincent, A.M., Callaghan, B.C., Smith, A.L. and Feldman, E.L. (2011) Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nature Reviews Neurology, 7, 573-583. 1038/nrneurol.2011.137

[3]   Vincent, A.M., Hinder, L.M., Pop-Busui, R. and Feldman, E.L. (2009) Hyperlipidemia: A new therapeutic target for diabetic neuropathy. Journal of the Peripheral Nervous System, 14, 257-267.

[4]   Obrosova, I.G. (2009) Diabetes and the peripheral nerve. Biochimica et Biophysica Acta, 1792, 931-940.

[5]   Veves, A., Backonja, M. and Malik, R.A. (2008) Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options. Pain Medication, 9, 660-674.

[6]   Beisswenger, P.J., Drummond, K.S., Nelson, R.G., Howell, S.K., Szwergold, B.S. and Mauer, M. (2005) Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes, 54, 3274-3281.

[7]   Beisswenger, P.J., Howell, S.K., Nelson, R.G., Mauer, M. and Szwergold, B.S. (2003) Alpha-oxoaldehyde metabolism and diabetic complications. Biochemical Society Transactions, 31, 1358-1363.

[8]   Beisswenger, P.J., Howell, S.K., Smith, K. and Szwergold, B.S. (2003) Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochimica et Biophysica Acta, 1637, 98-106.

[9]   Fleming, T., Cuny, J., Nawroth, G., Djuric, Z., Humpert, P.M., Zeier, M., Bierhaus, A. and Nawroth, P.P. (2012) Is diabetes an acquired disorder of reactive glucose metabolites and their intermediates? Diabetologia, 55, 1151-1155.

[10]   Lupachyk, S., Watcho, P., Shevalye, H., Vareniuk, I., Obrosov, A., Obrosova, I.G. and Yorek, M.A. (2013) Na+/ H+ exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in Type 1 diabetic rats. American Journal of Physiology: Journal of Membrane Biology, 305, E396-E404.

[11]   Askarova, S., Yang, X., Sheng, W., Sun, G.Y. and Lee, J.C. (2011) Role of a β-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A2 activation in astrocytes and cerebral endothelial cells. Neuroscience, 199, 375-385.

[12]   Ding, Y., Kantarci, A., Hasturk, H., Trackman, P.C., Malabanan, A. and Van Dyke, T.F. (2007) Activation of RAGE induces elevated O2-generation by mononuclear phagocytes in diabetes. Journal of Leukocyte Biology, 81, 520-527.

[13]   Yin, Q.Q., Dong, C.F., Dong, S.Q., Dong, X.L., Hong, Y., Hou, X.Y., Luo, D.Z., Pei, J.J. and Liu, X.P. (2012) AGEs induce cell death via oxidative and endoplasmic reticulum stresses in both human SH-SY5Y neuroblastoma cells and rat cortical neurons. Cellular and Molecular Neurobiology, 32, 1299-1309.

[14]   Bkaily, G., Nader, M., Avedanian, L., Jacques, D., Perrault, C., Abdel-Samad, D., D’Orleans-Juste, P., Gobeil, F. and Hazzouri, K.M. (2004) Immunofluorescence revealed the presence of NHE-1 in the nuclear membranes of rat cardiomyocytes and isolated nuclei of human, rabbit, and rat aortic and liver tissues. Canadian Journal of Physiology and Pharmacology, 82, 805-811.

[15]   Ford, P., Rivarola, V., Kierbel, A., Chara, O., Blot-Chabaud, M., Farman, N., Parisi, M. and Capurro, C. (2002) Differential role of Na+/H+ exchange isoforms NHE-1 and NHE-2 in a rat cortical collecting duct cell line. Journal of Membrane Biology, 190, 117-125.

[16]   Karmazyn, M., Sawyer, M. and Fliegel, L. (2005) The Na(+)/H(+) exchanger: A target for cardiac therapeutic intervention. Current Drug Target—Cardiovascular & Hematological Disorders, 5, 323-335.

[17]   Khan, I., Thomas, N. and Haridas, S. (2001) Expression and sub cellular localization of the sodium hydrogen exchanger isoform-1 in rat tissues: A possible functional relevance. Molecular and Cellular Biochemistry, 219, 153-161.

[18]   Lupachyk, S., Stavniichuk, R., Komissarenko, J.I., Drel, V.R., Obrosov, A.A., El-Remessy, A.B., Pacher, P. and Obrosova, I.G. (2012) Na+/H+-exchanger-1 inhibition counteracts diabetic cataract formation and retinal oxidative-nitrative stress and apoptosis. International Journal of Molecular Medicine, 29, 989-998.

[19]   Rieder, C.V. and Fliegel, L. (2003) Transcriptional regulation of Na+/H+ exchanger expression in the intact mouse. Molecular and Cellular Biochemistry, 243, 87-95. 21643608619

[20]   Zhao, P., Ma, M.C., Qian, H. and Xia, Y. (2005) Downregulation of delta-opioid receptors in Na+/H+ exchanger 1 null mutant mouse brain with epilepsy. Neuroscience Research, 53, 442-446.

[21]   Dyck, J.R. and Lopaschuk, G.D. (1998) Glucose metabolism, H+ production and Na+/H+-exchanger mRNA levels in ischemic hearts from diabetic rats. Molecular and Cellular Biochemistry, 180, 85-93.

[22]   Sun, Y.M., Su, Y., Li, J., Tian, Y. and Wang, L.F. (2012) Role of the Na(+)/H(+) exchanger on the development of diabetes mellitus and its chronic complications. Biochemical and Biophysical Research Communications, 427, 229-231.

[23]   Wang, S., Peng, Q., Zhang, J. and Liu, L. (2008) Na+/H+ exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain. Cardiovascular Research, 80, 255-262.

[24]   Obrosova, I.G., Pacher, P., Szabo, C., Zsengeller, Z., Hirooka, H., Stevens, M.J. and Yorek, M.A. (2005) Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-Ribose) polymerase activation in tissue sites for diabetes complications. Diabetes, 54, 234-242.

[25]   Drel, V.R., Pacher, P., Vareniuk, I., Pavlov, I., Ilnytska, O., Lyzogubov, V.V., Tibrewala, J., Groves, J.T. and Obrosova, I.G.(2007) A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. European Journal of Pharmacology, 569, 48-58.

[26]   Stavniichuk, R., Drel, V.R., Shevalye, H., Maksimchyk, Y., Kuchmerovska, T.M., Nadler, J.L. and Obrosova, I.G. (2011) Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation. Experimental Neurology, 230, 106-113.

[27]   Oltman, C.L., Davidson, E.P., Coppey, L.J., Kleinschmidt, T.L., Lund, D.D. and Yorek, M.A. (2008) Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity, 16, 82-89.

[28]   Peterson, R.G., Shaw, W.N. Neel, M.A, Little, L.A. and Eichberg, J. (1990) Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. The ILAR Journal, 32, 16-19.

[29]   Oltman, C.L., Coppey, L.J., Gellett, J.S., Davidson, E.P., Lund, D.D. and Yorek M.A. (2005) Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty (ZDF) and Zucker rats. American Journal of Physiology, 289, E113-E122.

[30]   Oltman, C.L., Davidson, E.P., Coppey, L.J., Kleinschmidt, T.L., Lund, D.D., Adebara, E.T. and Yorek, M.A. (2008) Vascular and neural dysfunction in Zucker diabetic fatty rats: A difficult condition to reverse. Diabetes, Obesity and Metabolism, 10, 64-74.

[31]   Putney, L.K., Denker, S.P. and Barber, D.L. (2002) The changing face of the Na+/H+ exchager, NHE1: Structure, regulation, and cellular actions. Annual Review of Pharmacology and Toxicology, 42, 527-552.

[32]   Erecinska, M., Thoresen, M. and Silver, I.A. (2003) Effects of hypothermia on energy metabolism in Mammalian central nervous system. Journal of Cerebral Blood Flow & Metabolism, 23, 513-530.

[33]   Lang, K.S., Mueller, M.M., Tanneur, V., Wallisch, S., Fedorenko, O., Palmada, M., Lang, F., Broer, S., Heilig, C.W., Schleicher, E. and Weigert, C. (2003) Regulation of cytosolic pH and lactic acid release in mesangial cells overexpressing GLUT1. Kidney International, 64, 1338-1347.

[34]   Peak, M., al-Habori, M. and Agius, L. (1992) Regulation of glycogen synthesis and glycolysis by insulin, pH and cell volume. Interactions between swelling and alkalinization in mediating the effects of insulin. Biochemical Journal, 28, 797-805.

[35]   Reshkin, S.J., Bellizzi, A., Caldeira, S., Albarani, V., Malanchi, I., Poignee, M., Alunni-Fabbroni, M., Casavola, V. andTommasino, M. (2000) Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. The FASEB Journal, 14, 2185-2197.

[36]   Jack, M. and Wright, D. (2012) Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Translational Research, 159, 355-365. trsl.2011.12.004

[37]   Sugimoto, K., Yasujima, M. and Yagihashi, S. (2008) Role of advanced glycation end products in diabetic neuropathy. Current Pharmaceutical Design, 14, 953-961. 161208784139774

[38]   Vial, G., Dubouchaud, H., Couturier, K., Lanson, M., Leverve, X. and Demaison, L. (2008) Na+/H+ exchange inhibition with cariporide prevents alterations of coronary endothelial function in streptozotocin-induced diabetes. Molecular and Cellular Biochemistry, 310, 93-102.

[39]   Coppey, L.J., Davidson, E.P., Rinehart, T.W., Gellett, J.S., Oltman, C.L., Lund, D.D. and Yorek, M.A. (2006) ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes, 55, 341-348. 02.06.db05-0885

[40]   Lewis, E.J., Hunsicker, L.G., Bain, R.P. and Rohde, R.D. (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine, 329, 1456-1462.

[41]   Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R. and Raz, I. (2001) Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. New England Journal of Medicine, 345, 851-860.

[42]   Yorek, M.A. (2008) The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy. Current Drug Targets, 9, 77-84. 2174/138945008783431736

[43]   Hannan, K.M. and Little, P.J. (1998) Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes. Biochemistry and Cell Biology, 76, 751-759. 1139/o98-093

[44]   Cukiernik, M., Hileeto, D., Downey, D., Evans, T., Khan, Z.A., Karmazyn, M. and Chakrabarti, S. (2004) The role of the sodium hydrogen exchanger-1 in mediating diabetesinduced changes in the retina. Diabetes/Metabolism Research and Reviews, 20, 61-71.

[45]   Anzawa, R., Seki, S., Nagoshi, T., Taniguchi, I., Feuvray, D. and Yoshimura, M. (2012) The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from Type 2 diabetic db/db mice. Cardiovascular Diabetology, 11, 33.

[46]   Chen, S., Khan, Z.A., Karmazyn, M. and Chakrabarti, S. (2007) Role of endothelin-1, sodium hydrogen exchanger-1 and mitogen activated protein kinase (MAPK) activation in glucose-induced cardiomyocte hypertrophy. Diabetes/ Metabolism Research and Reviews, 23, 356-367.

[47]   Darmellah, A., Baetz, D., Prunier, F., Tamareille, S., RuckerMartin, C. and Feuvray, D. (2007) Enhanced activity of the myocardial Na+/H+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of Type 2 diabetes: Critical role of Akt. Diabetologia, 50, 1335-13344.